Synchron Raises US$200 Million in Series D Financing
Synchron has secured US$200 million in a Series D funding round to fast-track the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform and to advance the development of a next-generation, transcatheter, high-channel whole-brain interface.
Funding Purpose and Goals
The new capital will support acceleration of pivotal clinical trials and preparations for the commercial launch of the Stentrode BCI system. The company also plans to expand its team by hiring engineers, neuroscientists, and operators to further develop the next generation of BCIs.
Lead and Participating Investors
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
Company Statement
“Bolstered by this Series D funding, Synchron will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs.”
Funding Overview
This latest financing round brings Synchron’s total funding to US$345 million, reinforcing its commitment to pioneering brain-computer interface technology.
Author’s summary: Synchron’s recent US$200 million Series D funding marks a major step forward in commercialising innovative BCI technologies and expanding its expert team.